Loomis, Sayles & Company
GBT

Loomis, Sayles & Company’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Loomis, Sayles & Company’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-324,183
Closed -$12.3M – 967
2018
Q3 		$12.3M Sell
324,183
-3,542
-1% -$157K 0.02% 327
2018
Q2 		$14.8M Buy
327,725
+31,743
+11% +$1.45M 0.03% 318
2018
Q1 		$14.3M Sell
295,982
-65,112
-18% -$3.63M 0.03% 336
2017
Q4 		$14.2M Buy
+361,094
New +$13.5M 0.03% 359

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company's GBT Position: Q4 2018 in Review

Loomis, Sayles & Company sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2018, closing a stake of 324,183 shares — an estimated $12.3M sold.

Loomis, Sayles & Company first reported a position in GBT in Q4 2017 and held it in 4 quarters. The position peaked at $14.8M in Q2 2018. 190 funds tracked by Wall St. Rank hold GBT as of Q4 2018.

  • Loomis, Sayles & Company reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2018 after selling out during the quarter.
  • Loomis, Sayles & Company sold 324,183 Global Blood Therapeutics, Inc. shares in Q4 2018, an estimated $12.3M.
  • Loomis, Sayles & Company first reported a position in Global Blood Therapeutics, Inc. in Q4 2017 and held it in 4 quarters.
  • Loomis, Sayles & Company's Global Blood Therapeutics, Inc. position peaked at $14.8M in Q2 2018.
  • 190 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2018.

Based on Loomis, Sayles & Company's 13F filing for Q4 2018, filed 14 Feb 2019.